CN102018663A - Preparation of compound/glucose - Google Patents
Preparation of compound/glucose Download PDFInfo
- Publication number
- CN102018663A CN102018663A CN2009102327515A CN200910232751A CN102018663A CN 102018663 A CN102018663 A CN 102018663A CN 2009102327515 A CN2009102327515 A CN 2009102327515A CN 200910232751 A CN200910232751 A CN 200910232751A CN 102018663 A CN102018663 A CN 102018663A
- Authority
- CN
- China
- Prior art keywords
- formula
- preparation
- glucose
- compound
- compound hydrochloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/04—Nitro compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Abstract
The invention relates to a water preparation of compound (hydrochloride/glucose) in formula (I), a preparation method of the preparation and an application of the preparation in preparing a medicine for preventing or treating bacterial infection of humans and animals.
Description
Technical field
The present invention relates to the preparation method of water formulation, said preparation of a kind of formula (I) compound hydrochloride and glucose and said preparation are used for preventing or treat the medicine of the mankind or animal bacterial infection in preparation application.
Background technology
To first quinolones synthetic antibiotic listing sixties, this type of medicine has obtained development rapidly.But along with the increasingly extensive application of fluoroquinolones, some antibacterial such as staphylococcus aureus, bacillus pyocyaneus etc. are to having produced drug resistance with the existing kind headed by the ciprofloxacin.In addition, part quinolinones kind exists than serious adverse, and therefore, early the second filial generation and even the application clinically of third generation quinolone antibiotic have begun to be restricted.
Of the present invention is a kind of formula (I) chemical compound, and it has the effect of effective wide spectrum bacterial-infection resisting, and described formula (I) chemical compound has the structural formula shown in following:
(9)-and fluoro-2,3-dihydro-3-methyl-8-amino-10-(4-methyl isophthalic acid-croak piperazine base)-7-oxo-7H-pyrido [1,2,3-de]-[1,4] benzoxazinyl-6-carboxylic acid
Patent CN1459288A has put down in writing adenosine cyclophosphate Portugal amine content assay method in a kind of meglumine adenosine cycle phosphate great transfusion preparation and preparation method thereof and this great transfusion preparation.The technical scheme of this invention is to contain glucose 4.5-5.5 gram in per 100 ml of formulation, meglumine adenosine cycle phosphate 54-66 milligram, all the other are water for injection, the pH scope is 3.5～5.5, this technical scheme has been determined key condition pH value scope and the great transfusion preparation preparation method thereof that the meglumine adenosine cycle phosphate great transfusion preparation is stable, and solved the meglumine adenosine cycle phosphate content assaying method, help control to the meglumine adenosine cycle phosphate great transfusion preparation quality of production, thereby formulate suitable production method, making the meglumine adenosine cycle phosphate great transfusion preparation be able to industrialized mass becomes possibility.
Chinese patent CN1562029A has put down in writing a kind of enoxacin intravenous fluid, and every liter of injection contains 10～60g enoxacin, 25.2～36.9g glucono-, and all the other are water for injection.Its method for making is: enoxacin and maltonic acid-delta-lactone are mixed, add in the water for injection, be heated to 55 ℃～60 ℃, stir, all dissolve to enoxacin and maltonic acid-delta-lactone mixture, add water for injection to 1 liter then, stir evenly, adding needle-use activated carbon stirs, leave standstill after-filtration and remove active carbon, be filtered to clear and bright, fill, seal, flowing steam sterilization promptly gets states the enoxacin intravenous fluid.The present invention adopts maltonic acid-delta-lactone and enoxacin to be mixed in enoxacin is dissolved fully, the enoxacin intravenous fluid that obtains thus is the clarity height not only, almost colourless or the little yellow of outward appearance, and can alleviate or eliminate the photosensitive toxicity of enoxacin and the red swelling of the skin, pain even the phlebitis that cause, safe in utilization and have no adverse reaction.
Patent CN1615869A Flunarizine hydrochloride injection and preparation method thereof is made of following component: flunarizine hydrochloride (g): 0.1mol/L sodium hydroxide solution (ml): water for injection or 5% or 10% glucose solution (ml) are 1～5: 0～250: 50000; Or flunarizine hydrochloride (g): 0.1mol/L hydrochloric acid (ml): 5% or 10% glucose solution (ml) is 1～5: 0～600: 1000000.Preparation method adopts preparation technology to solve the problems of dissolution of flunarizine hydrochloride, promptly at low temperatures, earlier flunarizine hydrochloride is joined in the solution, flunarizine hydrochloride is dispersed in the solution, and reheat fully dissolves flunarizine hydrochloride to higher temperature, so do not contain solubilizing agent and analgesic in the injection, thereby blood vessel and muscle do not had bad stimulation, easy to use, safe, evident in efficacy.
The preparation of said medicine chemical compound and glucose preparation, overcome the some shortcomings part of reactive compound on preparation, but when the hydrochlorate with formula (I) chemical compound was prepared into liquid preparation, it is unstability very, be easy to degraded or decomposition, such as under illumination.This is because contain similar beta-keto acid structure in formula (I) chemical compound, poor stability in sour environment, and easily decarboxylation under long-time illumination, thus lose activity; And be subjected to the influence of the amino donor residues of 5-, carboxyl is easier under long-time illumination loses for formula (I) compound hydrochloride, causes the reduction of content, pH value and the light transmission rate of formula (I) chemical compound.
Therefore, we need improve the aqueous stability of formula (I) compound hydrochloride by certain methods, and a kind of liquid preparation that comprises formula (I) compound hydrochloride aqueous solution especially is provided.
The applicant is after the long-term conscientious research of process, unexpectedly find, in the presence of certain density glucose, can significantly suppress the reduction of hydrochloride compound content, pH value and light transmission rate in formula (I) the compound hydrochloride aqueous solution and the formation of related substances, especially can stop the degraded of illumination following formula (I) compound hydrochloride at the glucose solution of a certain specific concentrations.Therefore, in the presence of particular range concentration glucose, the stability of the aqueous solution of formula (I) compound hydrochloride is significantly improved, and based on this, has finished the present invention.
Summary of the invention
An object of the present invention is to provide a kind of broad-spectrum antiseptic, formula (I) chemical compound/glucose preparation that antibacterial ability is strong, it specifically is a kind of water formulation as medicine, it contains formula (I) compound hydrochloride of 0.02%-1% (w/v) and the glucose of 0.1%-10% (w/v), and wherein said formula (I) chemical compound has structure as follows:
(9)-and fluoro-2,3-dihydro-3-methyl-8-amino-10-(4-methyl isophthalic acid-croak piperazine base)-7-oxo-7H-pyrido [1,2,3-de]-[1,4] benzoxazinyl-6-carboxylic acid.
In water formulation of the present invention, the content of formula (I) compound hydrochloride is preferably the 0.02%-1% (w/v) of described water formulation, 0.05%-0.5% (w/v) more preferably, is preferably 0.1%-0.3% (w/v) especially.Especially preferably contain have an appointment 0.1% (w/v) formula (I) compound hydrochloride, be equivalent to the preparation of about 100mg/100ml.
In water formulation of the present invention, the content of glucose is preferably the 0.1%-10% (w/v) of described water formulation, be preferably again 0.5%-8% (w/v), more preferably 3.0%-7% (w/v), be preferably 4.0%-6.0% (w/v) especially, especially preferred glucose content is about 4.0% (w/v), is equivalent to the preparation of about 4.0g/100ml.
In above-mentioned water formulation, wherein the pH value of solution is 3.0-6.0, and preferred pH value is 4.0-5.0, and particularly preferred pH value is between the 4.3-4.8.
In this article, term " % (w/v) " refers to that unit of weight is the quantity of gram in per 100 ml volumes, be g/100ml, for example " glucose of 0.10%-10% (w/v) " is meant in the described water formulation of 100 ml volumes, includes the glucose of 0.1-10g weight.
Except other has explanation, term " formula (I) compound hydrochloride " is meant that the activity substance content of formula (I) compound hydrochloride converts based on formula (I) chemical compound herein, and for example above-mentioned " formula (I) compound hydrochloride of 0.02%-2% (w/v) " refers to and contain 0.02%-2% (w/v) formula (I) chemical compound.
Water herein generally refers to water for injection, also can be the medicinal water that meets national relevant regulations.
Another object of the present invention provides the preparation method of formula (I) chemical compound/glucose preparation, and it comprises the steps:
(1) with glucose dissolving soluble in water, obtain D/W,
(2) adding formula (I) compound hydrochloride, and
(3) adjust pH value of aqueous solution to 3.0-6.0.
In above-mentioned steps (3) afterwards, can be according to pharmaceutical formulation, supplementing water is to scheduled volume.
In the preparation method of above-mentioned water formulation, the adjusting of pH value of aqueous solution adopts sodium hydroxide or hydrochloric acid solution to carry out, and for example adopts sodium hydroxide or the aqueous hydrochloric acid solution of 0.1mol/l, and the pH that regulates aqueous solution reaches 3.0-6.0, be preferably 4.0-5.0, more preferably 4.3-4.8.
After preparing water formulation of the present invention, carry out disinfection with suitable manner, be filled into then in the suitable containers and (also can after filling, sterilize).Described container can be glass container or plastic containers.This container material can contain the material with ad hoc fashion protection content, for example is protected from photo damage or is protected from oxygen to destroy.
The container that holds water formulation of the present invention can be the container of single dose or multiple-unit container, and it is including, but not limited to ampere bottle, vial, plastic bag, syringe etc.
The disinfection of water formulation of the present invention can prove effective under common mode, also can sterilize under special medical mode, for example filters or heating.Sterilization can carry out disinfection before or after aqueous solution is packed into container.
If needs are medically arranged, except containing glucose, also contain other pharmaceutically useful additive, in the water formulation of the present invention as cosolvent, buffer components, antiseptic, antioxidant or stabilizing agent etc.For example can add sodium salt, potassium salt, calcium salt and magnesium salt etc., and applied other the conventional adjuvant in their chloride, carbonate, sulfate, acetate, gluconate, lactate, malate and parenteral field, these excipient or adjuvant can randomly add before adjusting pH value of aqueous solution.
Water formulation of the present invention not only can use for example injection or drop by whole body, also can locally use as external or sprinkling.For example, water formulation of the present invention is as the parenteral medicine, in particular as the medicine of treatment or prevention bacterial infection.Parenteral for example comprises: intravenous, intra-arterial, subcutaneous, intramuscular and intraperitoneal administration.Wherein intravenous administration is topmost route of administration.Only dosage is 100mg/100ml formula (I) compound hydrochloride (based on the amount of formula (I) chemical compound), and every day, intravenous infusion was 1 time.The volume infused of administration every day should be no more than 500-600ml.
The present invention also provides the application of water formulation in preparation parenteral medicine of formula (I) compound hydrochloride as mentioned above, and described water formulation is used for preventing or treat the application of the medicine of the mankind or animal bacterial infection in preparation.
In water formulation of the present invention, the existence of glucose can enhanced (I) compound hydrochloride to the stability of light, especially reduce the coming off of 3 carboxyls of formula (I) chemical compound, with the stability of freeze mode (I) compound hydrochloride aqueous solution.We observe, even concentration of glucose just can observe the stablizing effect of formula (I) compound hydrochloride when 0.10% (w/v), and when concentration was 2.0%-7.0% (w/v), its stablizing effect was good especially.
The specific embodiment
Following embodiment with employing is explained in more detail the present invention, but content of the present invention is not limited to this.
Used formula (I) compound hydrochloride of the embodiment of the invention is provided by the global pharmaceutcal corporation, Ltd in Anhui.Hydrochloric acid, sodium hydroxide, glucose all are the reagent grades of national regulation.The water that uses is water for injection.
General preparation method
Following embodiment 1-12 of the present invention is according to being prepared as follows the method preparation: take by weighing a certain amount of glucose, add the dissolving of injection water, obtain glucose solution, add activated carbon and stir evenly, heated and boiled, filtered while hot decarburization; Take by weighing a certain amount of formula (I) compound hydrochloride then, add in the above-mentioned solution, stirring and dissolving is regulated pH value (as adopting the aqueous hydrochloric acid solution of 0.1mol/l) afterwards, adds to the full amount of water for injection at last, and stirring, filtration make it mixing.Add an amount of pin activated carbon then, return filter, cross microporous filter membrane (for example 0.45 μ m) and in infusion bottle, jump a queue, roll aluminium lid, heat sterilization (for example 115 ℃, 32 minutes) gets final product.
Formula (I) compound hydrochloride in following examples Chinese style (I) compound hydrochloride/G/W preparation all is based on the calculating of formula (I) chemical compound, promptly take by weighing 110g formula (I) compound hydrochloride and be equivalent to 100g formula (I) chemical compound, for example " formula (I) compound hydrochloride/G/W preparation; 0.1% (w/v) (100mg/100ml) " is meant that formula (I) compound hydrochloride content in aqueous solution is 0.1% among the embodiment 3, promptly contain 100mg formula (I) chemical compound in the 100ml aqueous solution, its corresponding formula (I) compound hydrochloride quality is 110mg.Other embodiment by that analogy.
Embodiment 1
Formula (I) compound hydrochloride/G/W preparation, 0.02% (w/v) (20mg/100ml)
* based on the amount of formula (I) chemical compound.
Embodiment 2
Formula (I) compound hydrochloride/G/W preparation, 0.05% (w/v) (50mg/100ml)
* based on the amount of formula (I) chemical compound.
Embodiment 3
Formula (I) compound hydrochloride/G/W preparation, 0.1% (w/v) (100mg/100ml)
* based on the amount of formula (I) chemical compound.
Embodiment 4
Formula (I) compound hydrochloride/G/W preparation, 0.1% (w/v) (100mg/100ml)
* based on the amount of formula (I) chemical compound.
Embodiment 5
Formula (I) compound hydrochloride/G/W preparation, 0.3% (w/v) (300mg/100ml)
* based on the amount of formula (I) chemical compound.
Embodiment 6
Formula (I) compound hydrochloride/G/W preparation, 0.5% (w/v) (500mg/100ml)
* based on the amount of formula (I) chemical compound.
Embodiment 7
Formula (I) compound hydrochloride/G/W preparation, 0.1% (w/v) (100mg/100ml)
* based on the amount of formula (I) chemical compound.
Embodiment 8
Formula (I) compound hydrochloride/G/W preparation, 1.0% (w/v) (1000mg/100ml)
* based on the amount of formula (I) chemical compound.
Embodiment 9
Formula (I) compound hydrochloride/G/W preparation, 0.5% (w/v) (500mg/100ml)
* based on the amount of formula (I) chemical compound.
Embodiment 10
Formula (I) compound hydrochloride/G/W preparation, 0.3% (w/v) (300mg/100ml)
* based on the amount of formula (I) chemical compound.
Embodiment 11
Formula (I) compound hydrochloride/G/W preparation, 0.1% (w/v) (100mg/100ml)
* based on the amount of formula (I) chemical compound.
Embodiment 12
Formula (I) compound hydrochloride/G/W preparation, 1% (w/v) (100mg/100ml)
* based on the amount of formula (I) chemical compound.
Stability test
A. determining instrument:
UV-1700 purple light spectrophotometer (day island proper Tianjin company);
UV intensity analyzer (UVC-254);
Uviol lamp (120W), wavelength: 200-400nm, (Chongqing Bulb Industry Co., Ltd);
(temperature: 25-35 ℃ of sunlight; Weather: fine; Intensity, big);
(temperature: 22-30 ℃ of natural light; The balcony limit).
B. measure the selection and the stability test of wavelength
Getting formula (I) the compound hydrochloride aqueous solution that does not contain glucose is standard solution, and is blank with the distilled water, in the interscan of 200-400nm wave-length coverage.Found that formula (I) compound hydrochloride 227,297 and 377nm absorption maximum is arranged, and impurity has absorption maximum about 297nm, so finally select the mensuration wavelength of 297nm as formula (I) compound hydrochloride.In addition, this solution is placed room temperature lucifuge place, measure 0,2 and 4 hour absorbance respectively, all no change almost shows that this stability of solution is good.
C. the stability of formula (I) compound hydrochloride aqueous solution under different light is measured
Accurate formula (I) the compound hydrochloride aqueous solution 1ml that does not contain glucose that draws, place irradiation under the ultraviolet light, and got in 0,1,2,3,4 hour different time period and to be diluted to the solution that concentration is about 5 μ g/ml in right amount, measure absorbance, calculate content and decline percent.Draw formula (I) the compound hydrochloride aqueous solution that does not contain glucose simultaneously, place the irradiation down of sunlight, natural light respectively, measure and calculating content and decline percentage ratio, the result is referring to table 1.
Table 1: the absorbance, concentration and the decline percentage ratio that do not contain formula (I) the compound hydrochloride aqueous solution of glucose under the different light
Result by table 1 can know, formula (I) the compound hydrochloride aqueous solution that does not contain glucose under the irradiation of three kinds of light sources, content in time prolongation and descend.Place under the illumination at the formula that does not contain glucose (I) compound hydrochloride aqueous solution, the speed of its degraded increases gradually.Formula (I) compound hydrochloride is unstable under illumination, and its catabolite may cause clinical untoward reaction.
D. controlled trial
(1), the preparation of test sample
Reference substance: the water formulation of the water for injection of preparation formula (I) compound hydrochloride 0.1% (w/v) (active component: based on the amount meter of formula (I) chemical compound) is as the blank product---sample 1;
Test article: according to the general preparation method preparation formula of the embodiment of the invention (I) compound hydrochloride/G/W formulation samples, get a certain amount of glucose, in 80ml water for injection, add not commensurability glucose (being respectively 0.1g, 0.5g, 2.0g, 4.0g, 5.0g, 6.0g, 7.0g or 10g), as sample 2-9.Add formula (I) compound hydrochloride 110mg (active component: be equivalent to 100mg formula (I) chemical compound) then respectively, stirring back use adjusting pH is about 4.0, add the injection water then respectively and be settled to 100ml, accurately take out 10ml and insert in the measurement bottle, with to be determined.
Get reference substance and test article 10ml respectively and place the measurement bottle, measure.
(2) assay method
According to above-mentioned c (formula (I) compound hydrochloride aqueous solution under different light stability measure) similar methods, with the accurate 1ml that draws of above-mentioned sample, place irradiation under the ultraviolet light (condition is consistent with above-mentioned c), and after 4 hours, get and be diluted to the solution that concentration is about 5 μ g/ml in right amount, measure absorbance, and calculate content and decline percent, and measuring and calculating content and decline percentage ratio, the result is referring to table 2.
Table 2: the absorbance, concentration and the decline percentage ratio that contain formula (I) the compound hydrochloride aqueous solution of glucose under the ultraviolet lighting
Result according to table 2 can know, formula (I) the compound hydrochloride aqueous solution that contains glucose under the irradiation of natural light, content in time prolongation and descend to some extent, but the speed that descends is greatly slowed down.It is evident that formula (I) compound hydrochloride aqueous solution adds has suppressed behind the glucose because the change of the chemical constituent that irradiation causes, has proved all that as the reduction of pH value, lowering of concentration percentage ratio the adding glucose can improve the stability of formula (I) compound hydrochloride aqueous solution.
Simultaneously, we are as can be seen from the data of table 2, when concentration of glucose when being low to moderate 0.1%, influence just exists to formula (I) compound hydrochloride aqueous stability, and wherein the decrease speed of sample 8 is minimum, this means that effect was the most obvious when concentration of glucose reached 7.0% left and right sides in formula (I) the compound hydrochloride aqueous solution.But also as can be seen, when surpassing 4.0%, concentration of glucose equally also can observe stable effect.
Claims (9)
1. water formulation as medicine, its contain 0.02%-1% (w/v) formula (I) compound hydrochloride and and the glucose of 0.1%-10% (w/v), wherein said formula (I) chemical compound has structure as follows:
(9)-and fluoro-2,3-dihydro-3-methyl-8-amino-10-(4-methyl isophthalic acid-croak piperazine base)-7-oxo-7H-pyrido [1,2,3-de]-[1,4] benzoxazinyl-6-carboxylic acid.
2. the water formulation of claim 1, it contains formula (I) compound hydrochloride of 0.05%-0.5% (w/v).
3. the water formulation of claim 1, it contains formula (I) compound hydrochloride of 0.1%-0.3% (w/v).
4. each water formulation among the claim 1-3, it contains the glucose of 0.5%-8.0% (w/v).
5. each water formulation among the claim 1-3, it contains the glucose of 2.0%-7.0% (w/v).
6. each water formulation among the claim 1-3, it contains the glucose of 4.0%-6.0% (w/v).
7. the preparation method of each water formulation among the claim 1-6, it may further comprise the steps:
(1) with glucose dissolving soluble in water,
(2) adding formula (I) compound hydrochloride, and
(3) adjust pH value of aqueous solution to 3.0-6.0.
8. the water formulation of each formula (I) compound hydrochloride is used for the application of the medicine of parenteral among the claim 1-6 in preparation.
9. the water formulation of each formula (I) compound hydrochloride is used for preventing or treat the application of the medicine of the mankind or animal bacterial infection among the claim 1-6 in preparation.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009102327515A CN102018663A (en) | 2009-11-30 | 2009-11-30 | Preparation of compound/glucose |
| PCT/CN2010/001875 WO2011063605A1 (en) | 2009-11-30 | 2010-11-22 | Compound / glucose preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009102327515A CN102018663A (en) | 2009-11-30 | 2009-11-30 | Preparation of compound/glucose |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102018663A true CN102018663A (en) | 2011-04-20 |
Family
ID=43860718
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009102327515A Pending CN102018663A (en) | 2009-11-30 | 2009-11-30 | Preparation of compound/glucose |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN102018663A (en) |
| WO (1) | WO2011063605A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102101865A (en) * | 2009-12-22 | 2011-06-22 | 江苏九寿堂生物制品有限公司 | Crystal form of carbostyril compound hydrochlorides |
| CN106109407A (en) * | 2016-08-25 | 2016-11-16 | 安徽环球药业股份有限公司 | The compound method of antofloxacin hydrochloride sodium chloride injection |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101081210A (en) * | 2006-06-02 | 2007-12-05 | 严明 | Carbostyrile antibiotic injection preparations |
-
2009
- 2009-11-30 CN CN2009102327515A patent/CN102018663A/en active Pending
-
2010
- 2010-11-22 WO PCT/CN2010/001875 patent/WO2011063605A1/en active Application Filing
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102101865A (en) * | 2009-12-22 | 2011-06-22 | 江苏九寿堂生物制品有限公司 | Crystal form of carbostyril compound hydrochlorides |
| CN106109407A (en) * | 2016-08-25 | 2016-11-16 | 安徽环球药业股份有限公司 | The compound method of antofloxacin hydrochloride sodium chloride injection |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011063605A1 (en) | 2011-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP957A (en) | Novel stable liquid paracetamol compositions, and method for preparing same. | |
| CA2559630C (en) | Fasudil-containing preparation and method of improving stability thereof | |
| AU771058B2 (en) | Moxifloxacin formulation containing common salt | |
| Vermeire et al. | Stability and compatibility of morphine | |
| CN106963759B (en) | Aqueous solutions comprising 3-quinuclidinone derivatives for the treatment of hyperproliferative diseases, autoimmune diseases and cardiac diseases | |
| JP4929352B2 (en) | Injectable paracetamol solution | |
| CN101455631B (en) | Meglumine cyclic adenosine injection and preparation technique thereof | |
| US20220378077A1 (en) | Ready-To-Use Parenteral Nutrition Formulation | |
| KR20020081293A (en) | Pharmaceutical Composition Comprising Pemetrexed Together With Monothioglycerol L-Cystein or Thioglycolic Acid | |
| CA2378425C (en) | Aqueous pharmaceutical formulation of moxifloxacin or salts thereof | |
| CN102018663A (en) | Preparation of compound/glucose | |
| CZ20023849A3 (en) | Novel pharmaceutical preparations based on alpha-(2,4-disulfophenyl)-N-tert-butylnitrone | |
| CN102018664A (en) | Preparation of compound/sodium chloride | |
| CN100516071C (en) | Amino butanetriol salt of cephalosporin compounds and preparing method | |
| JP2006083164A (en) | Transfusion product | |
| CN102258463A (en) | Stable sodium folinate injection | |
| CN100336510C (en) | Cefpiramide composition | |
| JP2003055195A (en) | Vitamin b1-formulated comprehensive transfusion for peripheral intravenous administration | |
| CN110314132B (en) | Ornithine aspartate injection and preparation method thereof | |
| CN102727429B (en) | Pidotimod injection with modified stability, and preparation method thereof | |
| CN101569612A (en) | Lyophilized clindamycin phosphate powder needle reagent | |
| CN107854486A (en) | The medical composition and its use of the various trace elements of injection | |
| WO2024027549A1 (en) | Pharmaceutical composition containing pyrrole gastric acid secretion inhibitor and preparation method therefor | |
| CN103446158B (en) | Pharmaceutical composition of cefmenoxime hydrochloride and pediatric compound amino acid injection | |
| CN108653259A (en) | The medical composition and its use of various trace elements IV |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20110420 |